Try our Advanced Search for more refined results

Astrazeneca AB v. Hanmi USA, Inc.

  1. February 26, 2014

    Fed. Circ. Won't Rehear IP Suit Over Hanmi's Nexium Generic

    The Federal Circuit on Tuesday refused AstraZeneca AB's request for an en banc rehearing of its patent dispute over Hanmi Pharmaceutical Co. Ltd.'s generic version of AstraZeneca's acid reflux drug Nexium, stymying AstraZeneca's efforts to block the generic.

  2. January 21, 2014

    AstraZeneca Seeks Full Rehearing Of Generic Drugmaker Win

    AstraZeneca AB on Tuesday asked for a full rehearing before the Federal Circuit in its ongoing efforts to block Hanmi USA Inc.'s generic version of acid reflux drug Nexium, arguing that a Federal Circuit panel disregarded precedent in upholding a lower court's claim construction.

  3. December 19, 2013

    Fed. Circ. Affirms Hanmi Win In Generic Nexium Patent Suit

    The Federal Circuit on Thursday found that Hanmi Pharmaceutical Co. Ltd.'s generic version of AstraZeneca AB's acid reflux drug Nexium does not infringe two of AstraZeneca's patents, upholding a lower court's construction of a key term in one of the patents.

  4. October 02, 2013

    Fed. Circ. Lifts Injunction On Hanmi's Generic Nexium

    The Federal Circuit has lifted a temporary injunction barring Hanmi USA Inc. from launching its generic version of AstraZeneca's acid reflux drug Nexium, in an appeal of a New Jersey court ruling that hindered AstraZeneca's patent infringement claims.

  5. September 05, 2013

    AstraZeneca Asks Fed. Circ. To Reopen Nexium Patent Suit

    AstraZeneca AB on Tuesday asked the Federal Circuit to revive its suit against Hanmi Pharmaceutical Co. Ltd., arguing a lower court had wrongly found that the South Korean drugmaker's copycat version of the acid reflux medication Nexium does not violate AstraZeneca's patents.